comparemela.com

Latest Breaking News On - Prnewswire delcath systems inc - Page 8 : comparemela.com

Delcath Systems Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

NEW YORK, March 27, 2023 /PRNewswire/ Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business. | March 27, 2023

United statesBen shamsianJohnr sylvesterGerard michelSerrado capitalInternational tollDrug administrationPrnewswire delcath systems incStonepine capital managementDelcath systems incCompany venture opportunity fundSingle center studyDelcath systemsHepatic delivery systemPrescription drug user fee actVivo capital

Delcath Systems Announces up to $85 Million Financing

/PRNewswire/ Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and.

United statesBen shamsianCanaccord genuityPrnewswire delcath systems incCompany seriesf convertible preferred stockCompany or delcathDrug administrationSerrado capitalDelcath systems incStonepine capital managementExchange commissionVivo capitalLogos capitalRosalind advisorsSeriesf convertible preferred stockSecurities act

Delcath Systems, Inc : Delcath Systems Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

NEW YORK, March 27, 2023 /PRNewswire/ Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported

United statesGerard michelBen shamsianJohnr sylvesterPrnewswire delcath systems incDrug administrationSingle center studyStonepine capital managementCompany venture opportunity fundDelcath systems incSerrado capitalInternational tollDelcath systemsHepatic delivery systemPrescription drug user fee actVivo capital

Delcath Announces Rotation of the Board of Directors Chairmanship; John R Sylvester Appointed New Chairman as Company Prepares for US Commercial Launch

/PRNewswire/ Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the.

United statesRoger stollJohnr sylvesterBen shamsianGerard michelPrnewswire delcath systems incDrug administrationBoston scientificExchange commissionBiocompatibles internationalDelcath systems incChief executive officerChief commercial officerInterventional oncologyInterventional vascularDevelopment officer

Delcath Systems Announces Updated Results from CHOPIN Phase 1b Trial Published in Cardiovascular and Interventional Radiology

/PRNewswire/ Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the.

United statesOlofsson baggeTaoj panJohnny johnBen shamsianClinical affairsAmerican society of clinical oncologyPrnewswire delcath systems incDrug administrationCollaborative ocular melanoma study group report noExchange commissionLeiden university medical centerDelcath systems incHepatic delivery systemMelphalan percutaneous hepatic perfusionIpilimumab plus nivolumab

vimarsana © 2020. All Rights Reserved.